

### **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listing of claims in this application.

### **LISTING OF CLAIMS**

1-45. (Cancelled)

46. (New) A double-stranded short interfering RNA (siRNA) molecule comprising a sense RNA strand and an antisense RNA strand, wherein the sense RNA strand comprises the sequence 5'-ucgagacccugggacau-3'.

47. (New) A composition comprising the double-stranded siRNA molecule of claim 46 and a suitable carrier.

48. (New) The composition of claim 47, further comprising an additional double-stranded nucleic acid molecule.

49. (New) The composition of claim 48, wherein the additional double-stranded nucleic acid molecule decreases the expression of a VEGFR1 or VEGFR2 gene.

50. (New) The composition of claim 49, wherein the additional double-stranded nucleic acid molecule decreases the expression of human VEGFR1.

51. (New) The composition of claim 49, wherein the additional double-stranded nucleic acid molecule decreases the expression of human VEGFR2.

52. (New) A composition comprising:

- (a) the double-stranded siRNA molecule of claim 46,
- (b) a double-stranded nucleic acid molecule that decreases the expression of human VEGFR1; and
- (c) a double-stranded nucleic acid molecule that decreases the expression of human VEGFR2.

53. (New) The composition of claim 47, further comprising a polymeric synthetic nucleic acid carrier.

54. (New) The composition of claim 53, wherein the polymeric synthetic nucleic acid carrier comprises a cationic polymer.

55. (New) The composition of claim 54, wherein the cationic polymer is an amino acid copolymer.

56. (New) The composition of claim 55, wherein the amino acid copolymer comprises histidine and lysine.

57. (New) The composition of claim 53, further comprising a targeting moiety.

58. (New) The composition of claim 57, wherein the targeting moiety comprises a peptide.

59. (New) The composition of claim 58, wherein the peptide comprises RGD amino acid sequence.

60. (New) The composition of claim 53, wherein the polymeric synthetic nucleic acid carrier comprises a hydrophilic polymer.

61. (New) The composition of claim 60, wherein the hydrophilic polymer comprises polyethyleneglycol.

62. (New) A method for reducing angiogenesis in a subject in need thereof, comprising the step of administering to the subject the double-stranded siRNA molecule of claim 46 or the composition of any one of claims 47, 49 and 52.

63. (New) A method of reducing tumor growth in a subject in need thereof, comprising the step of administering to the subject the double-stranded siRNA molecule of claim 46 or the composition of any one of claims 47, 49 and 52.

64. (New) A method for decreasing the VEGF protein level in a cell, comprising introducing into the cell the double-stranded siRNA molecule of claim 46 or the composition of any one of claims 47, 49 and 52.